TG Therapeutics (NASDAQ:TGTX) Hits New 1-Year High – Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $26.74 and last traded at $26.45, with a volume of 2850661 shares. The stock had previously closed at $25.06.

Wall Street Analyst Weigh In

TGTX has been the topic of several recent research reports. The Goldman Sachs Group boosted their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, TD Cowen started coverage on TG Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $50.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.43.

TG Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of 43.56 and a beta of 2.21. The company has a fifty day moving average price of $23.44 and a two-hundred day moving average price of $19.89.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. During the same quarter in the prior year, the firm posted ($0.34) earnings per share. The company’s revenue was up 357.0% on a year-over-year basis. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.12 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. acquired a new position in TG Therapeutics during the second quarter valued at $8,698,000. Marshall Wace LLP acquired a new position in TG Therapeutics during the second quarter valued at $36,501,000. Bank of New York Mellon Corp raised its position in TG Therapeutics by 13.4% during the second quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock valued at $8,960,000 after buying an additional 59,523 shares during the period. Cetera Advisors LLC acquired a new position in TG Therapeutics during the first quarter valued at $622,000. Finally, Russell Investments Group Ltd. raised its position in TG Therapeutics by 133.5% during the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 29,923 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.